ISSN: 2231-3656

International Journal of Pharmacy and Industrial Research (IJPIR)

IJPIR |Vol. 16 | Issue 3 | July-Sep 2026

www.ijpir.com

DOI: https://doi.org/10.61096/ijpir.v16.iss3.2026 772-790

Cell Cycle: A multi-nutrient complex targeting one-carbon metabolism, methylation and cellular health: a narrative review of the evidence for eleven micronutrient and phytochemical actives

Dr. Leroy Rebello[1], Dr. Sreesudha Chepyala[2], Sahithi Polineni[3]

Department: Research and Development, Biotex Life Solutions, Hyderabad, Telangana.

Correspondence Author: **Sahithi Polineni,**
sahithi.biotexlife@gmail.com

Published on: 21.07.2026
Published by: Futuristic Publications

Abstract:

Background: The homeostasis of the cell is maintained by tightly regulated and interconnected metabolic pathways such as folate-mediated one-carbon metabolism, the methylation cycle, glutathione redox system, and cofactor-dependent energy and glucose metabolism. The insufficiency of any trace elements that participate in the above-mentioned processes may disrupt their physiological function.

Scope: This narrative review aimed to provide a mechanistic basis for the reported clinical and experimental rationale for the use of the eleven-ingredient formulation containing L-methylfolate, cyanocobalamin, pyridoxal-5-phosphate, choline, myo-inositol, thiamine, D-biotin, alpha-lipoic acid, selenium, zinc, and chromium picolinate. Methylation has been used as a theoretical basis for this review, with individual ingredients being discussed in the context of their primary role rather than one overarching theme.

Findings: The combination of folate, vitamin B12, vitamin B6, and choline was consistently associated with the regulation of homocysteine and the promotion of remethylation and transsulfuration. Alpha-lipoic acid, selenium, and zinc were each involved in the maintenance of reduced glutathione and antioxidant defence, with the connections to methylation being primarily indirect but firmly established through transsulfuration. Thiamine and biotin acted as essential cofactors in numerous enzymatic reactions, while myo-inositol and chromium were beneficial for insulin function and glucose control, although the evidence for this aspect was inconsistent.

Conclusion: The reviewed formulation was mainly focused on methylation and interconnected biochemical pathways. While the most robust evidence was provided for the impact of the individual ingredients on methylation and antioxidant defence, the benefits in terms of improved glycemic control and cardiovascular risk reduction were limited and should be considered cautiously.

Keywords: DNA methylation; homocysteine; micronutrient supplementation; one-carbon metabolism; oxidative stress; redox homeostasis

1. Introduction

Human cells maintain their function, replicate their genome and defend themselves against oxidative injury through a small number of tightly interconnected biochemical networks. Among the most consequential of these is folate-mediated one-carbon metabolism, which supplies the activated methyl groups required for the synthesis of nucleotides and for the methylation of DNA, proteins and lipids.[1,2] Sitting immediately downstream is the methionine cycle, in which S-adenosylmethionine acts as the principal methyl donor for cellular methylation reactions, and its regeneration depends on the vitamin-dependent remethylation of

homocysteine.[3,4] The concentration of homocysteine in blood serves as a practical, widely measured indicator of the efficiency of these coupled cycles, rising when the supply of folate, vitamin B12, vitamin B6 or choline-derived methyl groups is inadequate.[3,5]

These pathways do not operate in isolation. The transsulfuration arm of homocysteine metabolism, driven by vitamin B6-dependent enzymes, diverts homocysteine toward the synthesis of cysteine and, ultimately, glutathione, the principal intracellular antioxidant.[6,7] In this way, the methylation network is biochemically continuous with the redox-defence network, which additionally depends on selenium-containing glutathione peroxidases, on zinc as a structural cofactor for antioxidant and DNA-repair enzymes and on alpha-lipoic acid as a redox-active cofactor capable of regenerating other antioxidant species.[8] A third axis, cofactor-dependent energy and glucose metabolism, links thiamine and biotin, as classical coenzymes of carbohydrate and lipid metabolism, to myo-inositol and chromium, which influence insulin signalling and glucose handling.[9,10,11]

The complex is best understood as a methylation core, comprising bioavailable methyl donors and the cofactors that regenerate them, complemented by redox-active and metabolic-cofactor nutrients that protect and sustain the same cellular machinery on which methylation depends. The rationale for combining these actives rests on this interconnection rather than on a single shared mechanism. A formulation that simultaneously supplies bioavailable methyl donors, the cofactors that regenerate them and the trace elements and redox agents that protect the cell reflects the way these pathways function in vivo, as a coupled system in which the output of one arm becomes the substrate of another (Figure 1).[3,4,7] At the same time, the evidence supporting each active is heterogeneous in both quantity and strength, and responsible synthesis requires that this heterogeneity be represented honestly rather than flattened into a uniform claim.

The practical relevance of such support rests on the observation that insufficiencies of folate, vitamin B12, vitamin B6, zinc and selenium remain common in specific population groups, including during pregnancy, in older adults and among those following restrictive diets, so that correction of marginal status is a plausible mechanism of benefit even where pharmacological effects in replete individuals are absent.

This review therefore examines the eleven actives of the complex using methylation and one-carbon metabolism as the organizing lens, assigning each active to the physiological role for which the evidence is strongest and making explicit, where relevant, its biochemical connection back to the methylation and DNA-health theme. It draws on original research published between 2016 and 2026, supplemented by recent quantitative syntheses, and maps the resulting claims to a tiered framework consistent with conservative, structure-function-based nutraceutical positioning. Throughout, it distinguishes endpoints that the evidence supports, such as homocysteine reduction and antioxidant-enzyme activity, from those it does not, most notably the reduction of cardiovascular events through homocysteine lowering, a distinction with direct regulatory and interpretive consequences.[5, 12]

2. Methods of the review

This narrative review was based on a structured search of PubMed/MEDLINE for literature published between 2016 and 2026. Searches were conducted separately for each of the eleven actives and for the cross-cutting mechanistic themes of one-carbon metabolism, methylation, redox homeostasis and insulin or glucose regulation, using single-concept queries to maximise topical precision. The full search strings for each active and theme, together with the publication-type filters and date limits applied, are provided in Supplementary Table S1 to support transparency and reproducibility. Priority was given to original research, comprising randomised controlled trials, other clinical trials, cohort and cross-sectional studies and experimental studies, with recent systematic reviews and meta-analyses from 2020 to 2026 retained where they provided the strongest available synthesis for a given active. Records were screened for topical relevance to the actives and their metabolic roles, and off-topic records arising from incidental keyword overlap were excluded. Retained references were deduplicated at the level of the PubMed identifier, and each digital object identifier was reconciled against authoritative registries and confirmed to be registered. The final evidence base comprised 85 references, of which the large majority were original studies. As a narrative rather than systematic review, this synthesis did not apply formal meta-analytic pooling or quantitative risk-of-bias scoring; its aim is interpretive integration rather than statistical estimation.

Assessment of safety and tolerability was integrated into the same screening process rather than conducted as a separate systematic search. For each active, adverse-event and tolerability data were extracted from three sources: the safety and adverse-event reporting within the retrieved randomised and clinical trials, which routinely document tolerability outcomes; the safety findings summarised in the

retained systematic reviews and meta-analyses; and established tolerable upper intake levels, contraindications and nutrient-nutrient interactions drawn from authoritative nutrition and regulatory references. Where a retrieved study reported dose-limiting effects, characteristic toxicity (for example selenosis or vitamin B6-associated sensory neuropathy), or analytical interference of clinical relevance (for example high-dose biotin in immunoassays), these were carried forward into the safety synthesis in Section 8. Because this was a narrative review, no formal quantitative pooling of adverse-event rates was performed; the safety account is therefore descriptive and is intended to flag formulation-relevant cautions rather than to estimate incidence. Exact upper-intake limits applicable to the finished product should be confirmed against the relevant regulatory schedules at the point of formulation and labelling.

2.1 Formulation composition

The composition of the reviewed complex is summarised in Table 1. Per-unit quantities are formulation-specific and are shown as representative categories; exact label amounts should be confirmed against the finished-product specification and applicable regulatory limits.

Table 1: Composition of the reviewed complex and functional roles

Active	Form	Primary functional role in the complex
L-methylfolate	L-5-methyltetrahydrofolate	Bioactive folate; methyl donor for homocysteine remethylation
Vitamin B12	Cyanocobalamin	Methionine synthase cofactor; folate-B12 remethylation
Vitamin B6	Pyridoxal-5-phosphate	Transsulfuration cofactor; glutathione precursor supply
Choline	Choline chloride	Betaine-pathway (folate-independent) methyl donor
Myo-inositol	Myo-inositol	Insulin second-messenger precursor; metabolic support
Vitamin B1	Thiamine mononitrate	Energy-metabolism coenzyme (transketolase, dehydrogenases)
Vitamin B7	D-biotin	Carboxylase cofactor; macronutrient metabolism
Alpha-lipoic acid	Alpha-lipoic acid	Redox cofactor; regenerates glutathione and other antioxidants
Selenium	Selenium (as selenite/selenomethionine)	Selenoprotein/glutathione-peroxidase cofactor
Zinc	Zinc sulphate	Antioxidant and DNA-synthesis/repair cofactor; immune support
Chromium	Chromium picolinate	Proposed insulin-potentiating trace element (conditional)



Fig 1: Schematic of the three interconnected metabolic axes



Fig 2: Integrated methylation, transsulfuration, redox, and metabolic-cofactor network. The methylation core, comprising folate, vitamin B_{12}, vitamin B_6, and choline, supports the regeneration of methionine and S-adenosylmethionine (SAM), the principal methyl donor required for cellular, epigenetic, and DNA methylation reactions, while contributing to the regulation of homocysteine concentrations. Homocysteine may be remethylated to methionine or diverted through the vitamin B_6-dependent transsulfuration pathway to form cysteine, a rate-limiting precursor for glutathione synthesis. This pathway connects one-carbon metabolism with the redox-protection axis, supported by alpha-lipoic acid, selenium-dependent glutathione peroxidases, and zinc-dependent antioxidant and cellular-protective systems. The surrounding energy and insulin-cofactor axis—including thiamine, biotin, myo-inositol, and chromium—supports carbohydrate metabolism, mitochondrial energy production, insulin signalling, and cellular metabolic homeostasis. Thiamine additionally supports pentose-phosphate-pathway activity through transketolase, indirectly contributing to NADPH generation required for glutathione recycling.

3. The methylation core

3.1 L-Methylfolate (L-5-methyltetrahydrofolate)

Mechanism and rationale. Folate is the entry point of one-carbon metabolism. Dietary and supplemental folates are reduced and interconverted through the folate cycle, culminating in 5-methyltetrahydrofolate, the circulating form that donates its methyl group to the remethylation of homocysteine to methionine.[1,3] L-Methylfolate is the bioactive, already-reduced form, and its inclusion in a complex is mechanistically deliberate: it bypasses the reductive steps catalysed by methylenetetrahydrofolate reductase, the enzyme whose common genetic variants reduce the efficiency of folic-acid activation.[3,4] Because 5-methyltetrahydrofolate feeds directly into the methionine cycle, adequate folate status is a precondition for

the regeneration of S-adenosylmethionine and therefore for cellular and DNA methylation, the biochemical link that anchors this active to the review's central theme.[1,4]

Evidence. The most consistent human evidence concerns homocysteine. Controlled supplementation studies show that folate, whether as folic acid or as reduced 5-methyltetrahydrofolate, lowers circulating homocysteine, and dose-finding work has sought to identify the intake that optimises this effect while avoiding unmetabolised folic acid.[3,13] A randomised controlled trial of combined methylfolate, pyridoxal-5-phosphate and methylcobalamin in individuals carrying methylenetetrahydrofolate reductase and related remethylation-pathway polymorphisms reported reductions in homocysteine, illustrating the rationale for delivering the active folate form together with its cofactor partners rather than in isolation.[4] Beyond homocysteine, exploratory intervention studies have examined folate-containing dietary and lifestyle programmes in relation to epigenetic-ageing markers, reporting shifts consistent with improved methylation capacity, though these findings are preliminary and require replication [14,15] [1,16]. Recent quantitative syntheses continue to define folate's role in specific populations and to map the boundaries of benefit [17,18,19] [20,21].

Interpretation and tier. The evidence supports a Tier 1 (Established) structure-function role for L-methylfolate in supporting one-carbon metabolism, methylation capacity and homocysteine regulation. Claims tied to epigenetic or DNA-health outcomes remain Tier 2 (Emerging), appropriate for cautious mechanistic language rather than asserted benefit. No disease-treatment claim is warranted.

A further consideration specific to this formulation is pharmacogenomic. Because common polymorphisms in methylenetetrahydrofolate reductase reduce the capacity to generate 5-methyltetrahydrofolate from folic acid, the use of the pre-reduced L-methylfolate form is a rational design choice that makes methyl-group availability less dependent on individual enzyme genotype. This does not constitute a personalised-medicine claim, but it provides a mechanistic rationale for selecting the active folate form in a general-population product.



Fig 3. Chemical structure, molecular characteristics, bioavailability, and principal physiological functions of L-methylfolate (L-5-methyltetrahydrofolate).

3.2 Cyanocobalamin (Vitamin B12)

Mechanism and rationale. Vitamin B12 is the obligatory cofactor for methionine synthase, the enzyme that transfers the methyl group from 5-methyltetrahydrofolate to homocysteine, regenerating methionine.[4,22] This places vitamin B12 at the exact node where the folate cycle and the methionine cycle intersect: without adequate vitamin B12, 5-methyltetrahydrofolate accumulates and cannot be used, the so-called methyl-folate trap, so folate and vitamin B12 are functionally inseparable in supporting methylation.[4,22] Cyanocobalamin is a stable, widely used supplemental form that is converted intracellularly to the active coenzymes; it is well absorbed, and although methylcobalamin is sometimes preferred for symmetry with

active folate, the active-form argument is weaker for vitamin B12 than for folate. Its inclusion alongside folate reflects the biochemical reality that methylation capacity depends on both together.

Evidence. Human evidence establishes vitamin B12 as rate-limiting for remethylation: deficiency raises homocysteine and methylmalonic acid, and repletion lowers them.[22,23] Dose-comparison trials have examined oral vitamin B12 regimens and their relative efficacy in restoring status, informing rational dosing within a complex.[22,24] Cross-sectional and cohort studies document the determinants and consequences of vitamin B12 status across life stages, including pregnancy and infancy, where adequate maternal vitamin B12 interacts with folate in supporting neural development.[25,23] A recent systematic review reinforces the folate and vitamin B12 interdependence at the population level, and formulation-oriented studies have compared delivery formats to optimise absorption [26,25,27].

Interpretation and tier. Vitamin B12's role as a methylation cofactor and homocysteine determinant is Tier 1 (Established). Its inclusion is mechanistically essential rather than additive. As with folate, extension to DNA-health outcomes is Tier 2 (Emerging) and should remain mechanistic in tone.

It is also worth distinguishing homocysteine's status as a biomarker from any causal role. Elevated homocysteine reliably signals inadequate remethylation and is lowered by folate and vitamin B12, but the failure of large homocysteine-lowering trials to reduce cardiovascular events indicates that homocysteine is better understood here as a marker of methylation-cycle adequacy than as a therapeutic target in its own right. This framing supports a methylation-support claim while explicitly declining a cardiovascular one.



Fig 4. Chemical structure, molecular characteristics, dietary sources, and principal physiological functions of cyanocobalamin (vitamin B_{12}).

3.3 Pyridoxal-5-phosphate (Vitamin B6)

Mechanism and rationale. Vitamin B6, in its coenzyme form pyridoxal-5-phosphate, is the cofactor for the transsulfuration pathway, comprising the enzymes cystathionine beta-synthase and cystathionine gamma-lyase, through which homocysteine is committed irreversibly to cysteine.[6,7] This is the second fate of homocysteine, complementary to vitamin B12 and folate-dependent remethylation, and it is the point at which the methylation network connects to redox defence: the cysteine produced is the rate-limiting

substrate for glutathione synthesis.[6,7] Vitamin B6 therefore belongs to the methylation core by virtue of controlling homocysteine's exit route, while simultaneously feeding the antioxidant axis discussed later, a genuine biochemical bridge rather than a rhetorical one.

Evidence. Vitamin B6 status is an established determinant of homocysteine, particularly of post-methionine-load homocysteine, which reflects transsulfuration capacity.[6,7] The combined methylfolate, pyridoxal-5-phosphate and methylcobalamin trial noted above supports the delivery of vitamin B6 alongside the remethylation cofactors for homocysteine control.[4] Intervention studies of folate combined with vitamin B6 and vitamin B12 have examined effects on homocysteine and related functional endpoints.[7,28] A recent synthesis has also examined vitamin B6 in specific symptomatic contexts, though such indications lie outside the structure-function scope of this complex and are noted only to characterise the evidence [29,30].

Interpretation and tier. Vitamin B6's role in transsulfuration and homocysteine handling is Tier 1 (Established). Its contribution to glutathione supply is mechanistically sound but should be described as supporting antioxidant capacity rather than producing a specific clinical antioxidant outcome.



Fig 5. Chemical structure, molecular characteristics, dietary sources, and principal physiological functions of pyridoxal-5′-phosphate (PLP), the active coenzyme form of vitamin B_6.

4 Choline (as choline chloride)

Mechanism and rationale. Choline provides a folate-independent route for homocysteine remethylation. Oxidised to betaine, it donates a methyl group via betaine-homocysteine methyltransferase, regenerating methionine in parallel with the folate and vitamin B12 pathway.[31,32] This redundancy is physiologically important: methylation capacity can be sustained through two complementary donor systems, which explains why choline is included alongside folate rather than as a substitute.[31,32] Choline is additionally a substrate for phospholipid and acetylcholine synthesis, but within this complex its methylation-relevant role, as a betaine-pathway methyl donor supporting the same methionine cycle as folate, is the one that ties it to the review's theme.

Evidence. Controlled studies show that betaine supplementation lowers homocysteine, confirming the functional activity of the choline and betaine remethylation route in humans.[33,31] Mechanistic and metabolomic work has examined choline-derived metabolites in relation to cardiometabolic pathways, illustrating both the reach and the complexity of choline metabolism.[34,32] Reviews of choline in pregnancy and neurodevelopment document its physiological importance, while trials of betaine on body-composition

and performance endpoints have generally not supported benefits beyond its biochemical effect on homocysteine, a useful boundary for claim-setting [35,33,36].

Interpretation and tier. Choline's betaine-pathway contribution to remethylation and homocysteine lowering is Tier 1 (Established). Broader performance or body-composition claims are Tier 3 (Excluded) and are explicitly not made. Its neurodevelopmental role is real but pertains to specific populations rather than to a general methylation-support claim.

4. The redox axis

The methylation core described above does not terminate at homocysteine. Through the vitamin B6-dependent transsulfuration pathway, homocysteine is converted to cysteine, the rate-limiting precursor of glutathione, the principal intracellular antioxidant.[6,7] This is the biochemical hinge on which the present complex turns: the same one-carbon machinery that sustains methylation also feeds the synthesis of the tripeptide that anchors redox defence. The three actives considered in this section, alpha-lipoic acid, selenium and zinc, operate within that redox network. They do not act as methyl donors, and this review does not represent them as such; rather, they protect and regenerate the glutathione-centred antioxidant system that is biochemically continuous with the methylation cycle, and in doing so they support the integrity of DNA and cellular components that methylation status is meant to preserve.[8]

4.1 Alpha-lipoic acid

Mechanism and rationale. Alpha-lipoic acid is a dithiol compound that functions both as an essential cofactor for mitochondrial dehydrogenase complexes in energy metabolism and as a redox-active antioxidant.[37,38] Its distinctive feature is amphiphilicity: it is active in both aqueous and lipid environments, and its reduced form, dihydrolipoic acid, can regenerate other antioxidants including glutathione, vitamin C and vitamin E.[37,38] This regenerative role is what links alpha-lipoic acid to the methylation-connected redox axis: by helping to maintain glutathione in its reduced, active state, it supports the antioxidant pool that transsulfuration supplies with cysteine.[37,38] Its inclusion in the complex is therefore rationalised not as a methyl donor but as a protector of the redox environment on which cellular and DNA integrity depend.

Evidence. Alpha-lipoic acid has the largest clinical-trial literature of the redox-axis actives, concentrated in glucose metabolism and oxidative-stress endpoints. Randomised trials and their syntheses show that supplementation improves markers of glycaemic control and reduces circulating oxidative-stress and inflammatory biomarkers in metabolically at-risk populations.[37,38,39] The best-established clinical application is symptomatic diabetic peripheral neuropathy, where oral alpha-lipoic acid has shown benefit in controlled evaluation, an indication that is clinically real but lies outside the structure-function scope of a general cellular-health complex and is noted here only to characterise the evidence, not to support a product claim [40,41,42,43,44] Further trials have examined effects on intermediate cardiometabolic and hepatic markers in overweight and obese adults, with effects that are measurable but modest [45,46,47,39,48].

Interpretation and tier. Alpha-lipoic acid's role in supporting redox homeostasis and antioxidant regeneration is Tier 1 (Established) at the mechanistic and biomarker level. Its glycaemic effects are Tier 2 (Emerging), real but variable in magnitude. Neuropathy benefit is a therapeutic indication and is Tier 3 (Excluded) for this product. The defensible claim is support for antioxidant and redox status, not treatment of any condition.

4.2 Selenium

Mechanism and rationale. Selenium exerts its biological effects almost entirely through selenoproteins, in which it is incorporated as selenocysteine.[49,50] The most relevant of these to this complex are the glutathione peroxidases, the enzyme family that uses reduced glutathione to detoxify hydrogen peroxide and lipid hydroperoxides.[49,50] This is the direct mechanistic junction with the methylation core: transsulfuration supplies the cysteine for glutathione synthesis, and selenium supplies the enzymatic machinery that puts that glutathione to work in antioxidant defence.[49,50] Selenium is thus positioned in the complex as the trace-element cofactor of the glutathione-dependent antioxidant system rather than as a methyl-cycle participant.

Evidence. Human evidence links selenium status to glutathione peroxidase activity and to immune and endocrine function. A systematic review and meta-analysis of experimental human studies supports a role for selenium in immune function, and controlled evidence documents effects in thyroid-related autoimmunity, where selenoprotein-dependent antioxidant activity is mechanistically implicated [51,52,49,50]. Trials have examined selenium supplementation in relation to insulin resistance and other metabolic markers, with mixed results that caution against strong metabolic claims [53,54,55,56]. Observational and

interventional data together indicate that selenium's benefits are most evident where baseline status is inadequate, consistent with a repletion rather than pharmacological model, an important boundary condition for a supplement.[50,56]

Interpretation and tier. Selenium's role as a cofactor for glutathione peroxidases and in antioxidant and immune support is Tier 1 (Established), strongest in the context of correcting insufficiency. Metabolic and endocrine effects are Tier 2 (Emerging) and context-dependent. Claims should emphasise antioxidant-enzyme support and be framed against adequacy of status, not as a universal benefit.

4.3 Zinc

Mechanism and rationale. Zinc is a structural and catalytic cofactor for hundreds of enzymes and for the zinc-finger motifs that stabilise DNA-binding proteins.[10,11,48] Two of its roles connect it directly to the concerns of this review. First, zinc contributes to antioxidant defence, both as a component of copper-zinc superoxide dismutase and by stabilising cellular thiols, complementing the glutathione-centred system supported by selenium and alpha-lipoic acid.[10,11,48] Second, zinc is required for the fidelity of DNA synthesis and repair and for the function of proteins that regulate genome stability, a link that ties it specifically to the DNA-health element of the review's theme.[10,11,48] Zinc is therefore positioned as a cofactor supporting both redox balance and DNA integrity rather than as a methyl-cycle component.

Evidence. Controlled human studies show that zinc supplementation affects immune and metabolic endpoints, particularly where intake is marginal. Trials and their syntheses report effects of zinc on glycaemic and insulin-resistance markers and on cardiovascular risk factors, with a GRADE-assessed review indicating measurable but heterogeneous effects.[10,11] Zinc status is an established determinant of immune competence, and repletion studies support its role in immune function [57,58,59].[10,11,48] As with selenium, the pattern of evidence indicates that benefit is clearest in the setting of insufficiency, and that zinc must be balanced against copper status in chronic supplementation, a formulation and safety consideration rather than an efficacy claim.[10,11,48]

Interpretation and tier. Zinc's role as an antioxidant and DNA-integrity cofactor is Tier 1 (Established) at the mechanistic level, with its DNA-health link being one of the more defensible connections to the review's title. Glycaemic and cardiovascular-risk-factor effects are Tier 2 (Emerging) and heterogeneous. Immune-support claims are defensible where framed against adequacy of status.

Taken together, alpha-lipoic acid, selenium and zinc constitute a redox-support cluster that is biochemically continuous with the methylation core through the shared currency of glutathione. None is a methyl donor, and the review does not claim otherwise; their contribution is to protect the cellular and genomic substrate that methylation status exists to preserve, and to do so most reliably where baseline micronutrient status is inadequate.[8]

An additional and often underappreciated point is that these redox actives interact with one another. Selenium and alpha-lipoic acid both bear on glutathione status, and their combined presence may support redox capacity more consistently than either alone; equally, such interactions can be antagonistic as well as additive, which is why the formulation's rationale is framed as coordinated nutritional support rather than as demonstrated multiplicative benefit.

5. The energy and insulin-cofactor axis

The third axis of the complex is the most loosely connected to methylation, and this review represents that distance honestly rather than obscuring it. Thiamine and biotin are classical coenzymes of energy metabolism whose relevance to cellular health is foundational but indirect; myo-inositol and chromium relate to insulin signalling and glucose handling, domains in which they have their own evidence base largely independent of the one-carbon cycle.[9,10,11] These actives are included as broad metabolic-support components, nutrients that sustain the energetic and glucoregulatory context within which methylation and redox reactions occur, and their claims are tiered accordingly, with the two glucose-related actives treated conservatively given the heterogeneity of their evidence.

5.1 Thiamine (Vitamin B1, as thiamine mononitrate)

Mechanism and rationale. Thiamine, in its coenzyme form thiamine pyrophosphate, is essential for the activity of transketolase in the pentose phosphate pathway and of the pyruvate and alpha-ketoglutarate dehydrogenase complexes in oxidative energy metabolism.[9,60] Its role is foundational to carbohydrate metabolism and to the generation of cellular energy and reducing equivalents. The link to this complex's theme is indirect but genuine: the pentose phosphate pathway that thiamine supports generates the NADPH required to maintain glutathione in its reduced state, connecting thiamine to the same redox-support

economy that underlies cellular and DNA integrity.[9, 60] Thiamine mononitrate is a stable supplemental form suited to multi-ingredient formulation.

Evidence. The clearest human evidence concerns deficiency and repletion: inadequate thiamine status impairs energy metabolism, and correction restores it, with deficiency states well characterised clinically.[60,61] In the metabolic domain, trials and syntheses have examined thiamine and its derivatives, including benfotiamine, in relation to glycaemic markers and diabetes, where thiamine status is often reduced; effects on glycaemic outcomes are inconsistent and generally modest.[9,61] Studies in acute and critical-illness settings have investigated thiamine's role in metabolic support, but these lie outside the scope of a general-wellness complex.

Interpretation and tier. Thiamine's role as an energy-metabolism cofactor is Tier 1 (Established) on the basis of well-understood biochemistry and deficiency data. Its glycaemic effects are Tier 2 (Emerging) and inconsistent. The defensible claim is support for normal energy metabolism; glucose-specific claims are not supported for this active.



Fig 6. Chemical structure, molecular characteristics, dietary sources, key physiological functions, and deficiency manifestations of thiamine (vitamin B_1).

5.2 D-Biotin (Vitamin B7)

Mechanism and rationale. Biotin is the covalently bound cofactor of the carboxylase enzymes that catalyse key steps in gluconeogenesis, fatty-acid synthesis and amino-acid catabolism.[62,63] It also participates in the regulation of gene expression, and its status affects a range of metabolic processes. Within this complex, biotin functions as a metabolic cofactor supporting carbohydrate and lipid metabolism; its connection to the methylation theme is the most distal of the eleven actives, and the review does not force one. It is included as a component of comprehensive B-vitamin metabolic support rather than as a methyl-cycle participant.

Evidence. Human evidence for biotin is dominated by deficiency and its correction: biotin deficiency, whether dietary or due to biotinidase deficiency, produces characteristic metabolic and dermatological features that resolve with repletion.[62,63] Beyond frank deficiency, the evidence for supplemental biotin producing benefit in replete individuals is limited, and this boundary is stated plainly here. Studies of combined micronutrient supplementation that include biotin report composite effects that cannot be attributed to biotin specifically.[63]

Interpretation and tier. Biotin's role as a carboxylase cofactor is Tier 1 (Established) at the level of essential biochemistry and deficiency correction. Independent supplemental benefit in replete individuals is Tier 3 (Excluded). Its inclusion is justified as part of B-complex adequacy, not as a standalone active with asserted benefit. A practical caution is that high-dose biotin can interfere with certain immunoassays, including thyroid-hormone and cardiac-troponin tests, a laboratory consideration relevant to labelling.



Fig 7. Chemical structure, molecular characteristics, dietary sources, key physiological functions, and deficiency manifestations of D-biotin (vitamin B7/vitamin H).

5.3 Myo-inositol

Mechanism and rationale. Myo-inositol is a carbocyclic polyol that serves as a precursor for phosphatidylinositol and for the inositol phosphoglycan second messengers involved in insulin signal transduction.[10,64] Its principal evidence-supported role is in insulin sensitivity and ovarian function, and it is included in this complex as a metabolic-support component in that domain. This review does not link myo-inositol to the one-carbon cycle, because the evidence does not support such a link; it is positioned honestly as a glucose- and insulin-related active whose rationale stands on its own literature.

Evidence. Myo-inositol has a substantial randomised-trial base, concentrated in two areas: polycystic ovary syndrome, where it improves ovulatory and metabolic parameters, and gestational-diabetes-related glycaemic measures, where trials and meta-analyses report improvements.[10,65,66] Comparative trials against metformin and other insulin sensitisers position myo-inositol as a reasonably tolerated option in these specific populations [67].[65,68,69] The evidence is strongest in these reproductive-metabolic contexts and does not generalise to a broad methylation or cellular-health claim.

Interpretation and tier. Myo-inositol's role in insulin signalling and in polycystic ovary syndrome and gestational-diabetes contexts is Tier 1 (Established) within those indications. As a general cellular-health or methylation-support claim it is Tier 3 (Excluded). Within this complex it warrants only a broad supports metabolic and insulin function structure-function framing, and its condition-specific evidence should not be imported as a general product claim.

5.4 Chromium (as chromium picolinate)

Mechanism and rationale. Chromium is proposed to potentiate insulin action, historically via the oligopeptide chromodulin, thereby influencing glucose and lipid metabolism.[11,56] Chromium picolinate is a commonly used, relatively bioavailable form. It is the active most distant from the methylation theme and the one with the weakest and most contested evidence; the review positions it as a conditional glucose-metabolism component and treats its claims with the greatest caution of any ingredient in the complex.

Evidence. The trial literature on chromium picolinate and glycaemic control is genuinely mixed. Meta-analyses report small effects on glucose and lipid measures in some diabetic populations, but effects are inconsistent, of uncertain clinical significance and not reliably reproduced in well-controlled trials; syntheses on body composition, blood pressure and lipid profile likewise show heterogeneous and often null results [70,71,72].[11,56] The essentiality of chromium in human nutrition itself has been questioned in authoritative reviews, further weakening the basis for strong claims.

Interpretation and tier. Chromium's glycaemic effect is Tier 2 (Emerging) at best and arguably Tier 3 for any firm claim. This review assigns chromium a conservative may support normal glucose metabolism framing only, with explicit acknowledgement of inconsistent evidence, and excludes any claim of glycaemic treatment, weight loss or cardiovascular benefit.

6. Rationale for the combination

The scientific case for combining these eleven actives rests on the interconnection of the pathways they serve rather than on additive independent effects. The methylation core, comprising L-methylfolate, cyanocobalamin, pyridoxal-5-phosphate and choline, is functionally interdependent: folate supplies the methyl group, vitamin B12 enables its transfer, vitamin B6 governs homocysteine's transsulfuration exit and choline provides a parallel remethylation route.[4,31] Delivering these together is mechanistically rational because a deficiency in any one constrains flux through the shared cycle, and because the co-administration of the active folate form with its vitamin B12 and vitamin B6 cofactors has been shown to lower homocysteine in a single intervention.[4] The transsulfuration output of this core connects to the redox cluster, comprising alpha-lipoic acid, selenium and zinc, through glutathione, the antioxidant whose synthesis depends on cysteine derived from homocysteine and whose function depends on selenium-containing peroxidases and zinc- and alpha-lipoic-acid-supported redox maintenance.[6,49,44] The energy and insulin-cofactor axis, comprising thiamine, biotin, myo-inositol and chromium, sustains the broader metabolic environment, with thiamine additionally feeding the NADPH supply that keeps glutathione reduced.[9,10]

This tri-axial structure is the honest scientific rationale for the complex: not that every ingredient methylates, but that the ingredients populate a connected network in which methylation, redox defence and energy metabolism are mutually dependent, and in which insufficiency at one node can propagate to others.[4,9] The combination is best understood as broad nutritional support for that network, with its strongest and most specific evidence residing in the methylation core. It should be noted that this rationale is mechanistic and complementary rather than a demonstration of synergistic clinical efficacy, which would require a trial of the finished formulation.

Two nutrient-interaction considerations reinforce the combination logic while also bounding it. Positively, the co-delivery of folate with vitamin B12 avoids the functional folate trap that can occur when folate is supplied without adequate vitamin B12, and the pairing of the transsulfuration cofactor vitamin B6 with the remethylation cofactors addresses both fates of homocysteine simultaneously. Cautionarily, chronic zinc intake can depress copper status and high folate intake can mask vitamin B12 deficiency, so the same interconnectedness that motivates the combination also imposes formulation constraints that responsible dosing must respect.

7. Tiered claim framework

The following table maps representative claims to their evidence tier and to a conservative structure-function framing suitable for a nutraceutical positioning under the FSSAI nutraceutical category. Tier 1 (Established) denotes claims supported by consistent human evidence and well-understood biochemistry; Tier 2 (Emerging) denotes biologically plausible claims with inconsistent or preliminary human support; Tier 3 (Excluded) denotes claims not supported for this product and deliberately not made. Table 2 presents this framework.

Table 2: Tiered claim framework for the complex

Active(s)	Claim domain	Tier	Permitted structure-function framing	Excluded (Tier 3)
L-methylfolate; B12	Methylation / homocysteine	Tier 1	Supports one-carbon metabolism and healthy homocysteine metabolism	Treats CV disease; reduces CV events
Vitamin B6	Transsulfuration; glutathione precursor	Tier 1	Supports homocysteine metabolism and antioxidant precursor supply	Treats neuropathy; disease claims
Choline	Betaine-pathway remethylation	Tier 1	Supports methyl-group metabolism	Weight loss; performance
Folate / B12	DNA / epigenetic health	Tier 2	Supports processes involved in DNA methylation (mechanistic)	Reverses ageing; treats disease

Active(s)	Claim domain	Tier	Permitted structure-function framing	Excluded (Tier 3)
Alpha-lipoic acid	Antioxidant / redox support	Tier 1	Supports antioxidant defence and redox balance	Treats diabetic neuropathy
Alpha-lipoic acid	Glycaemic support	Tier 2	May support normal glucose metabolism	Treats/controls diabetes
Selenium	Glutathione peroxidase; immune	Tier 1	Supports antioxidant-enzyme and immune function	Treats thyroid disease; cancer prevention
Zinc	Antioxidant + DNA repair; immune	Tier 1	Supports DNA integrity, antioxidant defence and immune function	Treats infection; CV event reduction
Thiamine	Energy metabolism	Tier 1	Supports normal energy-yielding metabolism	Glycaemic-control claims
Biotin	Macronutrient metabolism	Tier 1/3	Supports normal macronutrient metabolism	Hair/skin/nail efficacy if replete
Myo-inositol	Insulin / metabolic function	Tier 1/3	Supports metabolic and insulin function	General methylation claim
Chromium picolinate	Glucose metabolism	Tier 2	May support normal glucose metabolism	Weight loss; diabetes treatment; CV benefit

8. Safety, tolerability and upper intake considerations

The safety profile of the complex is generally favourable at nutritional doses, but several actives carry specific considerations that responsible formulation and labelling should address. Water-soluble vitamins, comprising folate, vitamin B12, vitamin B6, thiamine and biotin, have wide margins of safety, though chronically high vitamin B6 intake is associated with sensory neuropathy and warrants an upper limit, and high-dose biotin is a recognised source of interference in immunoassays including thyroid and cardiac-troponin tests.[60,62] Among the trace elements, selenium has a comparatively narrow therapeutic window, with excess intake producing selenosis, so dosing should respect established tolerable upper intake levels and account for background dietary intake.[49,50] Zinc supplementation over extended periods can impair copper status, making the zinc-to-copper balance a formulation consideration.[44,11] Chromium picolinate is generally well tolerated at supplemental doses, though its benefit-risk rationale is weak given the inconsistent efficacy evidence.[11,56] Alpha-lipoic acid and myo-inositol are well tolerated in trials, with mild gastrointestinal effects reported occasionally.[37,10] Across all actives, the evidence indicates that benefit is most reliable in the context of correcting insufficiency, and that supplementation should be positioned as nutritional support rather than pharmacological intervention. Exact tolerable upper intake levels should be verified against the applicable FSSAI schedules at the point of formulation and labelling.

9. Limitations and evidence gaps

Several limitations qualify the conclusions of this review. First and most importantly, the evidence synthesised here pertains to the individual actives, not to the finished multi-ingredient formulation; no clinical trial of the complex as a whole is available, and the combination rationale is therefore mechanistic rather than demonstrated in outcome terms. Second, the strength of evidence is uneven across the eleven actives, ranging from robust for the folate, vitamin B12 and vitamin B6 methylation core to weak and contested for chromium; presenting these uniformly would misrepresent the evidence, and the tiered framework is intended to prevent that. Third, much of the supporting evidence derives from populations with insufficiency or specific clinical conditions, and benefits observed under those circumstances may not translate to replete or general-wellness users. Fourth, as a narrative review, this synthesis did not apply systematic search protocols, formal risk-of-bias assessment or meta-analytic pooling, and is subject to the selection and interpretation limitations inherent to the format. Finally, and consistent with the wider literature, homocysteine lowering by B-vitamins has not been shown to reduce cardiovascular events in randomised trials, and the biochemical effects documented here should not be extrapolated to hard clinical outcomes.[5,12]

10. Conclusion

The eleven-component complex examined here is best understood as multi-pathway nutritional support organized around a methylation core. Its most substantiated actions lie in one-carbon metabolism and homocysteine regulation, supported by the folate, vitamin B12, vitamin B6 and choline group, and in glutathione-linked redox defence, supported by alpha-lipoic acid, selenium and zinc and connected to the methylation core through the transsulfuration pathway. The energy and insulin-cofactor actives, thiamine, biotin, myo-inositol and chromium, provide broader metabolic support with more variable evidence. Framed honestly and tiered by evidence strength, the complex offers a mechanistically coherent, structure-function-consistent approach to supporting cellular methylation and the metabolic environment on which it depends. Claims should remain strongest for methylation and redox endpoints and conservative for glycaemic outcomes, and no claim of cardiovascular-event reduction or disease treatment is warranted. Evaluation of the finished formulation in controlled human studies is the logical next step to substantiate the combination directly.

Declarations

Author contributions: All authors contributed equally to the conception, literature analysis, drafting and critical revision of this manuscript and approved the final version.

Conflict of interest: All authors are employed by Biotex Life Solutions Pvt. Ltd., the manufacturer of the product family to which the reviewed formulation belongs. This affiliation is disclosed in full. The authors received no additional payment for the preparation of this review, and the analysis was conducted with a deliberately conservative, evidence-led approach to claim-setting.

Funding: This work received no specific external grant funding.

Use of artificial intelligence: Literature retrieval, screening, reference verification and drafting support were assisted by artificial-intelligence tools, including large language models and cloud-based utilities. All references were drawn from PubMed/MEDLINE, and digital object identifiers were reconciled against authoritative registries. The authors reviewed and take full responsibility for the content.

Data availability: The reference set and verification records supporting this review are available from the corresponding author on reasonable request.

References

1. Villanueva JL, Vita AA, Zwickey H, et al.. Dietary associations with reduced epigenetic age: a secondary data analysis of the methylation diet and lifestyle study. *Aging* 2025. DOI: 10.18632/aging.206240
2. Zerback T, Koeder C, Weder S, et al.. Assessment of vitamin A, vitamin B2, vitamin B12, vitamin K, folate, and choline status following 4 months of multinutrient supplementation in healthy vegans: a randomised, double-blind, placebo-controlled trial. *European journal of nutrition* 2025. DOI: 10.1007/s00394-025-03814-7
3. Huang X, Bao H, Ding C, et al.. Optimal folic acid dosage in lowering homocysteine: Precision Folic Acid Trial to lower homocysteine (PFAT-Hcy). *European journal of nutrition* 2024. DOI: 10.1007/s00394-024-03344-8
4. Pokushalov E, Ponomarenko A, Bayramova S, et al.. Effect of Methylfolate, Pyridoxal-5'-Phosphate, and Methylcobalamin (SolowaysTM) Supplementation on Homocysteine and Low-Density Lipoprotein Cholesterol Levels in Patients with Methylenetetrahydrofolate Reductase, Methionine Synthase, and Methionine Synthase Reductase Polymorphisms: A Randomized Controlled Trial. *Nutrients* 2024. DOI: 10.3390/nu16111550
5. Guo L, Shi X, Wang G, et al.. Combined B-vitamin supplementation on homocysteine and vascular outcomes in coronary heart disease: a meta-analysis. *Annals of medicine* 2026. DOI: 10.1080/07853890.2026.2622208
6. Fu AS, Osman F, Cameron-Smith D, et al.. Micronutrient intake and status of adults consuming plant-based meat analogues or animal-based meats as primary protein source: An 8-week randomized controlled trial. *Clinical nutrition (Edinburgh, Scotland)* 2026. DOI: 10.1016/j.clnu.2026.106610

7. Akbarzadeh F, Talaei A, Nematy M, et al.. Short-Term Effects of Folate Supplementation in Combination With Vitamin B6 for Treating Acute Manic Episodes in Bipolar I Disorder: A Randomized Controlled Trial. *Brain and behavior* 2025. DOI: 10.1002/brb3.70432/v1/decision1
8. Fukatsu K, Shineha R, Kawauchi Y, et al.. Postoperative Vitamin Profile after Receiving a Novel Peripheral Parenteral Nutrition Solution: Multicenter Randomized Controlled Phase III Trial. *Annals of nutrition & metabolism* 2022. DOI: 10.1159/000524625
9. Ziegler D, Sipola G, Strom A, et al.. Effects of benfotiamine treatment over 12 months on morphometric, neurophysiological and clinical measures in type 2 diabetes patients with symptomatic polyneuropathy: a randomized, placebo-controlled, double-blind clinical trial (BOND study). *BMJ open diabetes research & care* 2026. DOI: 10.1136/bmjdrc-2025-005773
10. Antoniotti V, Partenope C, Solito A, et al.. Efficacy of myo-inositol and zinc on insulin resistance in a paediatric population with obesity. *Diabetes, obesity & metabolism* 2025. DOI: 10.1111/dom.16185/v2/decision1
11. Jenkins T, Aston K, Carrell D, et al.. The impact of zinc and folic acid supplementation on sperm DNA methylation: results from the folic acid and zinc supplementation randomized clinical trial (FAZST). *Fertility and sterility* 2022. DOI: 10.1016/j.fertnstert.2021.09.009
12. Finkelstein JL, Fothergill A, Venkatramanan S, et al.. Vitamin B12 supplementation during pregnancy for maternal and child health outcomes. *The Cochrane database of systematic reviews* 2024. DOI: 10.1002/14651858.cd013823
13. Vezzoli A, Dellanoce C, Caimi TM, et al.. Influence of Dietary Supplementation for Hyperhomocysteinemia Treatments. *Nutrients* 2020. DOI: 10.3390/nu12071957
14. Liu Z, Jin P, Liu Y, et al.. A comprehensive approach to lifestyle intervention based on a calorie-restricted diet ameliorates liver fat in overweight/obese patients with NAFLD: a multicenter randomized controlled trial in China. *Nutrition journal* 2024. DOI: 10.1186/s12937-024-00968-8
15. Li X, Shao X, Xue Q, et al.. DNA Methylation Near CPT1A and Changes in Triglyceride-rich Lipoproteins in Response to Weight-loss Diet Interventions. *The Journal of clinical endocrinology and metabolism* 2023. DOI: 10.1210/clinem/dgad086
16. Fitzgerald KN, Hodges R, Hanes D, et al.. Potential reversal of epigenetic age using a diet and lifestyle intervention: a pilot randomized clinical trial. *Aging* 2021. DOI: 10.18632/aging.205700
17. Sauer C, Hoang MA, Kroeun H, et al.. Assessing the adherence and acceptability to iron and folic acid compared with multiple micronutrient supplements during pregnancy: a cluster-randomized noninferiority trial in Cambodia. *The American journal of clinical nutrition* 2025. DOI: 10.1016/j.ajcnut.2025.04.033
18. DiTosto JD, Caniglia EC, Hinkle SN, et al.. Target trial emulation of preconception serum vitamin D status on fertility outcomes: a couples-based approach. *Fertility and sterility* 2025. DOI: 10.1016/j.fertnstert.2024.08.332
19. Christian P, Zavala E, Hurley KM, et al.. Prenatal and preschool micronutrient supplementation and behavioral outcomes in school-aged children in Nepal-a cohort study. *The American journal of clinical nutrition* 2025. DOI: 10.1016/j.ajcnut.2025.10.006
20. Eleotério MR, Ferreira LS, Azevedo FM, et al.. Folate Intake and Breast Cancer Risk: A Systematic Review and Meta-Analysis. *Molecular nutrition & food research* 2026. DOI: 10.1002/mnfr.70354
21. Aweke MN, Alhur AA, Baykemagn ND, et al.. Global folate deficiency among adolescent girls: A systematic review and meta-analysis. *PloS one* 2026. DOI: 10.1371/journal.pone.0346599
22. Mansour A, Amrollahi Bioky A, Gerami H, et al.. Efficacy of Oral Vitamin B-12 at 1000 μg Compared with 2000 μg on Neuropathic Outcomes in Patients with Diabetic Peripheral Neuropathy and Low Serum Vitamin B-12: a Randomized Clinical Trial. *The Journal of nutrition* 2026. DOI: 10.1016/j.tjnut.2026.101368
23. Bjørkevoll SMG, O'Keeffe M, Konijnenberg C, et al.. Infant vitamin B12 status and its predictors - cross-sectional baseline results from an ongoing randomized controlled trial. *The American journal of clinical nutrition* 2025. DOI: 10.1016/j.ajcnut.2025.06.029

24. Angelopoulos N, Paparodis RD, Androulakis I, et al.. Effects of a Novel Dispersible Supplement Containing 2500 IU of Vitamin D and 1000 µg of B12 in Restoring Vitamin D and B12 Insufficiency: A Multicenter, Randomized Controlled Trial. *Nutrients* 2025. DOI: 10.3390/nu17030419
25. Nie L, Liu X, Li X, et al.. Beyond Folate: The Emerging Role of Maternal Vitamin B12 in Neural Tube Development. *Nutrients* 2025. DOI: 10.3390/nu17122040
26. Didangelos T, Karlafti E, Kotzakioulafi E, et al.. Efficacy and Safety of the Combination of Palmitoylethanolamide, Superoxide Dismutase, Alpha Lipoic Acid, Vitamins B12, B1, B6, E, Mg, Zn and Nicotinamide for 6 Months in People with Diabetic Neuropathy. *Nutrients* 2024. DOI: 10.3390/nu16183045
27. Ko J, Yoo C, Xing D, et al.. Pharmacokinetic Analyses of Liposomal and Non-Liposomal Multivitamin/Mineral Formulations. *Nutrients* 2023. DOI: 10.3390/nu15133073
28. Michels AJ, Butler JA, Uesugi SL, et al.. Multivitamin/Multimineral Supplementation Prevents or Reverses Decline in Vitamin Biomarkers and Cellular Energy Metabolism in Healthy Older Men: A Randomized, Double-Blind, Placebo-Controlled Study. *Nutrients* 2023. DOI: 10.3390/nu15122691
29. Lacasa M, Alegre-Martin J, Sentañes RS, et al.. Yeast Beta-Glucan Supplementation with Multivitamins Attenuates Cognitive Impairments in Individuals with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. *Nutrients* 2023. DOI: 10.3390/nu15214504
30. Sharifipour F, Siahkal SF, Bagherinia M, et al.. The effectiveness of vitamin B6 in reducing mastalgia: a systematic review and meta-analysis. *BMC women's health* 2025. DOI: 10.1186/s12905-025-03991-x
31. Trujillo-Gonzalez I, Horita DA, Stegall J, et al.. Choline and betaine concentrations in plasma discriminate levels of dietary choline intake in healthy adults: analysis of a double-blind randomized crossover controlled feeding study. *The American journal of clinical nutrition* 2026. DOI: 10.1016/j.ajcnut.2026.101236
32. Derbyshire EJ. Choline in Pregnancy and Lactation: Essential Knowledge for Clinical Practice. *Nutrients* 2025. DOI: 10.3390/nu17091558
33. Nieman DC, Sakaguchi CA, Williams JC, et al.. Betaine Supplementation Improves 60 km Cycling Time Trial Performance and One-Carbon Metabolism in Cyclists During Recovery. *Nutrients* 2025. DOI: 10.3390/nu17172765
34. Gavilán IS, Li S, Sweet MG, et al.. A pilot and feasibility analysis of serum TMAO and choline in a randomized sample from the COSMOS trial. *Food & function* 2025. DOI: 10.1039/d5fo02596f/v1/decision1
35. Kerksick CM. Acute Alpha-Glycerylphosphorylcholine Supplementation Enhances Cognitive Performance in Healthy Men. *Nutrients* 2024. DOI: 10.3390/nu16234240
36. Wozniak JR, Eckerle JK, Gimbel BA, et al.. Choline enhances elicited imitation memory performance in preschool children with prenatal alcohol exposure: a cumulative report of 3 randomized controlled trials. *The American journal of clinical nutrition* 2025. DOI: 10.1016/j.ajcnut.2025.02.009
37. Tutunchi H, Arefhosseini S, Ebrahimi-Mameghani M, et al.. Clinical effectiveness of α-lipoic acid, myo-inositol and propolis supplementation on metabolic profiles and liver function in obese patients with NAFLD: A randomized controlled clinical trial. *Clinical nutrition ESPEN* 2023. DOI: 10.1016/j.clnesp.2023.02.016
38. Wang C, Qiao J, Liu S, et al.. Selenium in the treatment of mild-to-moderate Graves' orbitopathy: a 5-year prospective controlled cohort study. *Endocrine* 2024. DOI: 10.1007/s12020-023-03672-5
39. Zhang H, Yang Y, Liu S, et al.. Clinical efficacy of selenium supplementation in patients with Hashimoto thyroiditis: A systematic review and meta-analysis. *Medicine* 2025. DOI: 10.1097/md.0000000000044043
40. Hodeeb YM, El-Rewiny EM, Gaafar AM, et al.. The effect of alpha lipoic acid supplementation on sperm functions in idiopathic asthenozoospermic patients: a case-controlled study. *Human fertility (Cambridge, England)* 2023. DOI: 10.1080/14647273.2021.2025271
41. El-Nahas MR, Elkannishy G, Abdelhafez H, et al.. Oral Alpha Lipoic Acid Treatment for Symptomatic Diabetic Peripheral Neuropathy: A Randomized Double-Blinded Placebo-Controlled

Study. *Endocrine, metabolic & immune disorders drug targets* 2020. DOI: 10.2174/1871530320666200506081407

42. Zárate E, Velásquez-Reyes LV, Carlos Espindola-Reyes J, et al.. Combination therapy with pregabalin and thioctic acid offers safer pain control in diabetic neuropathy: a multicenter, double-blind, non-inferiority trial. *Brain communications* 2026. DOI: 10.1093/braincomms/fcag058
43. Cheng Q, Fan D, Chen P, et al.. Effect of selenium supplementation on hemodialysis patients: a meta-analysis. *International urology and nephrology* 2025. DOI: 10.1007/s11255-025-04400-w
44. Kim SA, Kim S, Chai H, et al.. Increasing Natural Killer Cell Activity of Mineral Nanomaterial ALP1018 in Healthy Adults: A Randomized, Double-Blind, Placebo Comparative Clinical Trial. *Nutrients* 2024. DOI: 10.3390/nu16060850
45. Kelley RL, Lee YSL, Agresta F, et al.. A prospective randomized controlled trial of antioxidants in human IVF and embryo culture media. *Human reproduction (Oxford, England)* 2025. DOI: 10.1093/humrep/deaf183
46. Pingarrón Santofímia C, Poyo Torcal S, López Verdú H, et al.. Evaluation of the efficacy of an antioxidant combination for the modulation of metabolic, endocrine, and clinical parameters in patients with polycystic ovary syndrome. *Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology* 2023. DOI: 10.1080/09513590.2023.2227277
47. Mandani M, Badehnoosh B, Jalali-Mashayekhi F, et al.. Alpha-lipoic acid supplementation effects on serum values of some oxidative stress biomarkers in women with gestational diabetes. *Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology* 2021. DOI: 10.1080/09513590.2021.1963955
48. Hosseini R, Montazerifar F, Shahraki E, et al.. The Effects of Zinc Sulfate Supplementation on Serum Copeptin, C-Reactive Protein and Metabolic Markers in Zinc-Deficient Diabetic Patients on Hemodialysis: A Randomized, Double-Blind, Placebo-Controlled Trial. *Biological trace element research* 2022. DOI: 10.1007/s12011-021-02649-7
49. Hayman T, Hickey P, Amann-Zalcenstein D, et al.. Zinc Supplementation with or without Additional Micronutrients Does Not Affect Peripheral Blood Gene Expression or Serum Cytokine Level in Bangladeshi Children. *Nutrients* 2021. DOI: 10.3390/nu13103516
50. Kim YM, Baek J. Effect of zinc supplementation on premenstrual symptoms: A systematic review and meta-analysis. *Women & health* 2025. DOI: 10.1080/03630242.2025.2539815
51. Le Moli R, Piticchio T, Pallotti F, et al.. Mediterranean diet, selenium and Graves' ophthalmopathy: a prospective, randomized, single-center study. *Endocrine* 2025. DOI: 10.1007/s12020-025-04360-2
52. Rossi M, Meomartino L, Zavattaro M, et al.. Adding L-Carnitine and Selenium to Methimazole in Graves' Disease: A Prospective Randomized Trial on Thyroid Markers and Quality of Life. *Nutrients* 2025. DOI: 10.3390/nu17162693
53. Vasto S, Di Rosa L, Ferrantelli V, et al.. Selenium-Biofortified Strawberries Improve Glucose Homeostasis and Hepatic Function: A 30-Day Randomized Controlled Trial in Healthy Adults. *Nutrients* 2026. DOI: 10.3390/nu18132078
54. Alehagen U, Aaseth J, Schomburg L, et al.. Selenoprotein P increases upon selenium and coenzyme Q10 supplementation and is associated with telomere length, quality of life and reduced inflammation and mortality. *Free radical biology & medicine* 2024. DOI: 10.1016/j.freeradbiomed.2024.06.027
55. Haas M, Brandl B, Schinhammer L, et al.. Individualized Supplementation of Immunoactive Micronutrients and Severity of Upper Respiratory Infection Symptoms-A Randomized Intervention Study. *Nutrients* 2024. DOI: 10.3390/nu16101400
56. Ancu O, Mackenzie RWA, Patterson M, et al.. Impact of a mineral enriched, fiber complex on glycaemic response and satiation in healthy adults: a double-blind, crossover intervention study. *European journal of nutrition* 2025. DOI: 10.1007/s00394-025-03732-8
57. Nobles C, Canty TP, Mendola P, et al.. Heat exposure during susceptible windows of spermatogenesis and sperm epigenetic age. *Human reproduction (Oxford, England)* 2026. DOI: 10.1093/humrep/deag048

58. de Vargas LDS, Jantsch J, Fontoura JR, et al.. Effects of Zinc Supplementation on Inflammatory and Cognitive Parameters in Middle-Aged Women with Overweight or Obesity. *Nutrients* 2023. DOI: 10.3390/nu15204396
59. Kewcharoenwong C, Sein MM, Nithichanon A, et al.. Daily preventive zinc supplementation increases the antibody response against pathogenic Escherichia coli in children with zinc insufficiency: a randomised controlled trial. *Scientific reports* 2022. DOI: 10.1038/s41598-022-20445-8
60. Tao Y, Wu M, Su B, et al.. Impact of Vitamin B1 and Vitamin B2 Supplementation on Anxiety, Stress, and Sleep Quality: A Randomized, Double-Blind, Placebo-Controlled Trial. *Nutrients* 2025. DOI: 10.3390/nu17111821
61. Bönhof GJ, Sipola G, Strom A, et al.. BOND study: a randomised double-blind, placebo-controlled trial over 12 months to assess the effects of benfotiamine on morphometric, neurophysiological and clinical measures in patients with type 2 diabetes with symptomatic polyneuropathy. *BMJ open* 2022. DOI: 10.1136/bmjopen-2021-057142
62. Tabriz N, Uslar VN, Obonyo D, et al.. Micronutritional status after pylorus preserving duodenopancreatectomy: analysis of data from a randomized controlled trial. *Scientific reports* 2021. DOI: 10.1038/s41598-021-97438-6
63. Perin J, Prokopowicz G, Furtado M, et al.. A Randomized Trial of a Novel Chewable Multivitamin and Mineral Supplement Following Roux-en-Y Gastric Bypass. *Obesity surgery* 2018. DOI: 10.1007/s11695-018-3177-0
64. Chan SY, Zhang H, Wong JT, et al.. Higher early pregnancy plasma myo-inositol associates with increased postprandial glycaemia later in pregnancy: Secondary analyses of the NiPPeR randomized controlled trial. *Diabetes, obesity & metabolism* 2024. DOI: 10.1111/dom.15468/v1/review1
65. Nazirudeen R, Sridhar S, Priyanka R, et al.. A randomized controlled trial comparing myoinositol with metformin versus metformin monotherapy in polycystic ovary syndrome. *Clinical endocrinology* 2023. DOI: 10.1111/cen.14931
66. Zhang J, Zhang H, Zhou W, et al.. Effect of myo-inositol supplementation in mixed ovarian response IVF cohort: a systematic review and meta-analysis. *Frontiers in endocrinology* 2025. DOI: 10.3389/fendo.2025.1520362
67. Andavar M, Kamaraj R, Mahalingam Vijayakumar T, et al.. Effectiveness of dual combination therapy of acarbose plus metformin and acarbose plus myo-inositol in ameliorating the metabolic and endocrinologic complications of polycystic ovary syndrome - A randomized controlled trial. *European journal of obstetrics, gynecology, and reproductive biology* 2024. DOI: 10.1016/j.ejogrb.2024.07.001
68. Soldat-Stanković V, Popović-Pejičić S, Stanković S, et al.. The effect of metformin and myoinositol on metabolic outcomes in women with polycystic ovary syndrome: role of body mass and adiponectin in a randomized controlled trial. *Journal of endocrinological investigation* 2022. DOI: 10.1186/isrctn13199265
69. Kelly FA, de Oliveira Macena Lôbo A, Cardoso JHCO, et al.. Comparison of metformin with inositol versus metformin alone in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. *Endocrine* 2025. DOI: 10.1007/s12020-024-04052-3
70. Ebrahimzadehkour B, Jambarsang S, Karimpour F, et al.. The Effect of Chromium Picolinate Supplementation on Cardiometabolic Biomarkers, Tumor Necrosis Factor-α Gene Expression, and DNA Damage in Subjects with Metabolic Syndrome: a Randomized Placebo-Controlled Clinical Trial. *Biological trace element research* 2026. DOI: 10.1007/s12011-025-04950-1
71. Martinez V, McAngus K, Dickerson BL, et al.. Effects of 12 Weeks of Chromium, Phyllanthus emblica Fruit Extract, and Shilajit Supplementation on Markers of Cardiometabolic Health, Fitness, and Weight Loss in Men and Women with Risk Factors to Metabolic Syndrome Initiating an Exercise and Diet Intervention: A Randomized Double-Blind, Placebo-Controlled Trial. *Nutrients* 2025. DOI: 10.3390/nu17122042
72. Buccato DG, Ullah H, De Lellis LF, et al.. Efficacy and Tolerability of a Food Supplement Based on Zea mays L., Gymnema sylvestre (Retz.) R.br.ex Sm, Zinc and Chromium for the Maintenance of

Normal Carbohydrate Metabolism: A Monocentric, Randomized, Double-Blind, Placebo-Controlled Clinical Trial. *Nutrients* 2024. DOI: 10.3390/nu16152459